<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">774</article-id><article-id pub-id-type="doi">10.36691/RJA774</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE GENETIC AND CLINICAL ASPECTS OF HAE, NEWPOSSIBILITIES OF THE DISEASE EXACERBATIONS TREATMENT</article-title><trans-title-group xml:lang="ru"><trans-title>ГЕНЕТИЧЕСКИЕ И КЛИНИЧЕСКИЕ АСПЕКТЫНАСЛЕДСТВЕННОГО АНГИООТЕКА, НОВЫЕВОЗМОЖНОСТИ КУПИРОВАНИЯ ОБОСТРЕНИЯ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Latysheva</surname><given-names>Tat'yana Vasil'evna</given-names></name><name xml:lang="ru"><surname>Латышева</surname><given-names>Татьяна Васильевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГБУ «ГНЦ Институт иммунологии» ФМБА России</p></bio><email>tvlat@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Polyakov</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Поляков</surname><given-names>А В</given-names></name></name-alternatives><bio xml:lang="ru"><p>Государственное учреждение Медико-генетический научный центр РАМН</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dmitrieva</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Дмитриева</surname><given-names>А В</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГБУ «ГНЦ Институт иммунологии» ФМБА России</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Medunitsyna</surname><given-names>E N</given-names></name><name xml:lang="ru"><surname>Медуницына</surname><given-names>Е Н</given-names></name></name-alternatives><bio xml:lang="ru"><p>ФГБУ «ГНЦ Институт иммунологии» ФМБА России</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Latysheva</surname><given-names>T V</given-names></name><bio xml:lang="en"><p>Institute of Immunology Moscow, Russia</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Polyakov</surname><given-names>A V</given-names></name><bio xml:lang="en"><p>Research Centre for Medical Genetics, RAMS</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Dmitrieva</surname><given-names>A V</given-names></name><bio xml:lang="en"><p>Institute of Immunology Moscow, Russia</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Medunitsyna</surname><given-names>E N</given-names></name><bio xml:lang="en"><p>Institute of Immunology Moscow, Russia</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Государственное учреждение Медико-генетический научный центр РАМН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Immunology Moscow, Russia</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Research Centre for Medical Genetics, RAMS</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2011</year></pub-date><volume>8</volume><issue>3</issue><issue-title xml:lang="en">NO3 (2011)</issue-title><issue-title xml:lang="ru">№3 (2011)</issue-title><fpage>14</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Фармарус Принт Медиа</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2013-09-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/774">https://rusalljournal.ru/raj/article/view/774</self-uri><abstract xml:lang="en"><p>Continued study of genetic and clinical aspects of hereditary angioedema (HAE) types I and II, which belongs
to the group of primary (genetically determined) immunodeficiencies and is connected with the qualitative or
quantitative genetically determined defect of C1 Inhibitor. HAE is an «orphan» disease and requires the establishment
of a Government strategy for patients with this rare diagnosis. To improve the quality of HAE diagnostics,
the Institute of Immunology jointly with Medical Genetics Centre started the work in order to develop and
introduce the methods of genetic screening of patients with recurrent angioedema into the national practice.
In the world as well as in Russian medical practice a new generation of medicines for the treatment of HAE attacks
has been appeared. Integrated assessment of the problems of diagnostics and treatment of HAE and their
consistent solution will significantly improve the quality of life of HAE patients.</p></abstract><trans-abstract xml:lang="ru"><p>Продолжается изучение генетических и клинических аспектов наследственного ангиоотека (НАо) I и
II типов, который относится к группе первичных (генетически детерминированных) иммунодефицитов
и связан с качественным или количественным дефектом ингибитора эстеразы компонента комплемента
C1 (С1-ингибитора). НАо относится к малым «сиротским» заболеваниям и требует разработки государственной стратегии в отношении пациентов с этой редкой нозологией, принимая во внимание тяжесть ее
течения. С целью повышения качества диагностики НАо в ФГБУ «ГНЦ Институт иммунологии» ФМБА
России совместно с Медико-генетическим научным центром РАМН начата работа по освоению и внедрению методов генетического обследования пациентов с рецидивирующими ангиоотеками. в мировой
и отечественной практике отмечается появление перспективных лекарственных препаратов нового
поколения, разработанных для лечения обострения заболевания. Комплексная оценка проблем диагностики и лечения НАо и их последовательное решение позволят в значительной степени оптимизировать
жизнь пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hereditary angioedema</kwd><kwd>HAE</kwd><kwd>C1 esterase inhibitor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>наследственный ангиоотек (НАо)</kwd><kwd>С1-ингибитор</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Викулов Г.Х., Феденко Е.С., Латышева Т.В. и соавт. Дифференциальная диагностика и принципы терапии наследственного ангионевротического отека (анализ клинического наблюдения). Леч. врач. 2004, № 3, с. 28-34.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Хаитов Р.М., Гущин И.С., Ильина Н.И. и соавт. Клиническая аллергология. Под ред. Р.М. Хаитова. М., 2002, с. 580-582.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bruce L., Zuraw M.D. Hereditary Angioedema. New Eng. j. Med. 2008, p. 1027-1036.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Wouters D., Wagenaar-Bos I., Marieke van Ham &amp; Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1-inhibitor. Expert. Opin. Biol. Ther. 2008, v. 8 (8), p. 1225-1240.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cichon S., Martin L., Hennies H.Ch. et al. Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III. Am. j. Human Genetics. 2006, v. 79, p. 1098-1104.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dewald G., Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Communications. 2006, v. 343, p. 1286-1289.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Weinstock L.B, Kothari T., Sharma R.N., Rosenfeld S.I. Recurrent abdominal pain as the sole manifestation of hereditary angioedema in multiple family members. Gastroenterology. 1987, v. 93 (5), p. 1116-1118.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cugno M., Castelli R., Cicardi M. Angioedema due to acquired C1 inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation. Autoimmunity Reviews. 2008, v. 8, p. 156-159.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Svetomir N., Markovic, David j. et al. Acquired C1 Esterase Inhibitor Deficiency. Ann. Intern. Med. 2000, v. 132, p. 144-150.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lear S., Heelan B., Longhurst H. Наследственный ангионевротический отек: рациональная терапия улучшает качество жизни и может спасти жизнь пациента. Аллер- гология. Научно-практич. журн. 2004, № 4, с. 48-54.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Davis A.E., Whitehead A.S., Harrison R.A. et al. Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Biochemistry. 1986, v. 83 (10), p. 3161-3165.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Varga L., Bors A., Tordai A. et al. Diagnostic pitfalls in hereditary angioedema. Abstract Book. XIth Meeting of the European Society for Immunodeficiencies (ESID). 2010, p. 137.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Quastel M., Harrison R., Cicardi M. et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. journal Clinical Investigation. 1983, v. 71 (4) p. 1041-1046.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kramer j., Rosen F.S., Colten H.R. et al. Transinhibition of C1-inhibitor synthesis in type I hereditary angioneurotic edema. journal Clinical Investigation. 1993, v. 91 (3), p. 1258-1262.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Verpy E., Biasotto M., Brai M. et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am. j. Hum. Genet. 1996, v. 59 (2) p. 308-319.</mixed-citation></ref></ref-list></back></article>
